Jean Jacques Bienaime - 12 May 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
12 May 2023
Net transactions value
-$602,250
Form type
4
Filing time
16 May 2023, 17:22:29 UTC
Previous filing
15 May 2023
Next filing
16 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $2,653,405 +39,130 +9.2% $67.81 465,343 12 May 2023 Direct
transaction BMRN Common Stock Options Exercise $499,760 +7,370 +1.6% $67.81 472,713 12 May 2023 Direct
transaction BMRN Common Stock Tax liability $595,234 -6,337 -1.3% $93.93 466,376 12 May 2023 Direct
transaction BMRN Common Stock Tax liability $3,160,181 -33,644 -7.2% $93.93 432,732 12 May 2023 Direct
holding BMRN Common Stock 247,333 12 May 2023 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 12 May 2023 Shares held as UTMA custodian for child
holding BMRN Common Stock 100 12 May 2023 Shares held as UTMA custodian for child

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -39,130 -100% $0.000000* 0 12 May 2023 Common Stock 39,130 $67.81 Direct F1
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -7,370 -100% $0.000000* 0 12 May 2023 Common Stock 7,370 $67.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the number of options outstanding after the transactions from this specific stock option grant.